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Abstract Genetic rearrangements involving the anaplastic lymphoma kinase (ALK) gene
confer sensitivity to ALK tyrosine kinase inhibitors (TKIs) and superior outcome in non-
small-cell lung cancer (NSCLC). However, clinical courses vary widely, and recent studies
suggest that molecular profiling of ALK+ NSCLC can provide additional predictors of ther-
apy response that could assist further individualization of patientmanagement. As repeated
tissue biopsies often pose technical difficulties and significant procedural risk, analysis of
tumor constituents circulating in the blood, including ctDNA and various proteins, is in-
creasingly recognized as an alternative method of tumor sampling (“liquid biopsy”).
Here, we report the case of a KLC1–ALK-rearranged NSCLC patient responding to crizoti-
nib treatment and demonstrate how analysis of plasma and serum biomarkers can be used
to identify theALK fusion partner andmonitor therapy over time. Results of ctDNA sequenc-
ing and copy-number alteration profiling as well as serum protein concentrations at various
time points during therapy reflected the current remission status and could predict the sub-
sequent clinical course. At the time of disease progression, we identified four distinct
secondary mutations in the ALK gene in ctDNA potentially causing treatment failure,
accompanied by rising levels of CEA and CYFRA 21–1. Moreover, several copy-number var-
iations were detected at the end of the treatment, including an amplification of a region on
Chromosome 12 encompassing the TP53 regulator MDM2. In summary, our findings illus-
trate the utility of noninvasive longitudinal molecular profiling for assessing remission status,
exploring mechanisms of treatment failure, predicting subsequent clinical course, and dis-
secting dynamics of drug-resistant clones in ALK+ lung cancer.
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CASE PRESENTATION
A 66-yr-old woman without significant comorbidities was diagnosed with metastatic ad-
enocarcinoma of the right lung including ipsilateral pleural and diffuse bone spread
(T2N0M1c). Initial treatment with carboplatin/pemetrexed chemotherapy resulted in a par-
tial remission after two cycles and was followed by pemetrexed maintenance. Meanwhile,
an ALK rearrangement was detected by fluorescence in situ hybridization (FISH).
Subsequent RNA next-generation sequencing (NGS) of the tumor identified transcripts
of KLC1 exon 9 fused with ALK exon 20 (K9–A20). Retrospective targeted deep sequenc-
ing of circulating tumor DNA (ctDNA) from several longitudinal blood plasma samples col-
lected at different time points confirmed the translocation and identified the DNA
breakpoints in KLC1 intron 9 and ALK intron 19 (Fig. 1A). The first plasma sample, collect-
ed at the time of partial remission after two cycles of carboplatin/pemetrexed chemother-
apy, showed a variant allele frequency (VAF) of 0.09% for the ALK fusion and no single-
nucleotide variants (SNVs) in the ALK gene (Fig. 1B). Analysis of a simultaneously collected
serum sample revealed a low abundance of CEA (39.52 ng/µL) and CYFRA 21–1 (0.53 ng/
µL; Fig. 1C). Two months after initiation of pemetrexed maintenance, the progression of
the primary tumor and pleural effusion was noted by chest CT (Fig. 1D, I1), and new cere-
bral metastases were detected by brain MRI (Fig. 1D, I2). At this timepoint, the retrospec-
tively determined KLC1–ALK fusion VAF rose to 6.25% and the tumor protein markers
CEA, CYFRA 21–1 were also increased. Second-line treatment with crizotinib (250 bid)
was initiated, and the patient initially responded with tumor shrinkage of ∼40%, as deter-
mined by radiological imaging (Fig. 1D, I3). During the next disease progression with mul-
tiple new brain lesions 50 d later (Fig. 1D, I4), the fusion VAF in retrospective analysis was
4.4% (i.e., lower than at the time of the previous systemic progression). However, four dis-
tinct secondary mutations in the kinase domain of the ALK gene were identified in ctDNA:
ALK p.F1174C (c.35221T>G) with 0.08% VAF, ALK p.F1174L (c.3522C>G with 0.88% VAF
and c.3522C>A with 0.24% VAF), and ALK p.G1269A (c.3806G>C) with 0.18% VAF (Fig.
1B). After whole-brain radiotherapy with 30 Gy (10 fractions of 3 Gy), clinical and radiolog-
ical follow-up during the following three months indicated stable disease, wherefore crizo-
tinib treatment was continued. However, a plasma sample taken only 3 wk after the last
radiation dose retrospectively revealed rising VAFs of the fusion KLC1–ALK (8.01%) and
all four secondary ALK variants, the most abundant of which was ALK p.F1174
(c.3522C>G with 3.26% VAF; Fig. 1B). At the same time, CEA and CYFRA 21–1 concentra-
tions were also elevated (Fig. 1C). In accordance with the rising VAFs and protein levels,
and despite the apparently stable radiologic findings, multilocular disease progression oc-
curred just 1 mo later, with multiple new lung and bone metastases as confirmed by PET-
CT. Retrospective molecular reassessment with liquid biopsy at that time point showed
steadily high VAFs, whereas concentrations of protein markers rose further (CEA: >155
ng/µL, CYFRA 21–2: >200 ng/µL; Fig. 1B,C). Based on the radiologic progression, crizo-
tinib treatment was discontinued and a switch to ceritinib was planned, but the patient
died before the therapy could be started. We also performed retrospective shallow
whole-genome sequencing (sWGS) of ctDNA from a plasma sample after two cycles of
carboplatin/pemetrexed and from the last sample upon progression under crizotinib.
Although sWGS of ctDNA during the first months after diagnosis revealed no copy-num-
ber variations (CNVs) with a trimmed median absolute deviation from copy-number neu-
trality (t-MAD) of 0.0098, noticeable alterations were detected at the end of the treatment
(t-MAD=0.0414), including an amplification of the region encompassing the TP53 regu-
lator MDM2 on Chromosome 12 (Fig. 1C,E).
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Figure 1. (A) Schematic of the predicted genomic translocation of KLC1–ALK and aligned ctDNA reads in IGV
spanning the rearrangement of KLC1 intron 8 and ALK intron 19. (B) Kinetics of mutated allele frequencies de-
tected in ctDNA during treatment. Corresponding images (I1–I4) are shown in E. Phases of stable disease and
progressive disease are indicated on top. (C ) Kinetics of serum protein concentrations during treatment.
Corresponding images (I1–I4) are shown in D. Phases of stable disease and progressive disease are indicated
on top. (D) Corresponding chest CT of the primary tumor (on the left; I1, I3) and brain MRI images of cerebral
metastases (on the right; I2, I4) taken during the therapy course. (E) Copy-number profiles of Chromosome 12
from sWGS of ctDNA. The upper panel shows the CNV profile before crizotinib treatment initiation; the bot-
tom panel shows the CNV profile at the end of treatment. (SD) Stable disease, (PD) progressive disease, (CTx)
chemotherapy, (RTx) whole-brain radiotherapy.
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TECHNICAL ANALYSIS AND METHODS
The histological diagnosis of lung adenocarcinoma was performed by experienced pulmo-
nary pathologists on a formalin-fixed and paraffin-embedded (FFPE) biopsy of the primary
tumor. The presence of theALK rearrangement was determined by fluorescent in situ hybrid-
ization (FISH) using ALK break-apart probes (ZytoLight SPEC ALK probe, ZytoVision). A fu-
sion transcript with exon 9 of KLC1 fused to ALK exon 20 (K9–A20) was confirmed by RNA
NGS using the AmpliSeq RNA Lung Cancer Fusion Panel (Thermo Fisher Scientific) as de-
scribed previously (Pfarr et al. 2016; Volckmar et al. 2019).
For ctDNA analysis, plasma was isolated from blood samples, centrifuged within 30 min
of collection, and processed with the AVENIO ctDNA Analysis Kit according to the manufac-
turer’s instructions (Roche Diagnostics). Briefly, cell-free DNAwas isolated from 2mL of plas-
ma using the AVENIO cfDNA Isolation Kit (Roche) and quantifiedwith theQubit dsDNAHigh
Sensitivity Kit (Thermo Fisher). Targeted sequencing libraries were prepared from 39.9 ng
DNA in median (range 24.5–50 ng) using the AVENIO ctDNA Library Preparation Kit with
the AVENIO Targeted and Surveillance Panel (both from Roche) for hybridization-based en-
richment of a 17-gene (81-kb) and a 197-gene (198-kb) panel, respectively. Among their tar-
get regions, both panels are designed to capture the exons 19 to 28 as well as intron 19 of
the ALK gene. CtDNA libraries from all plasma samples were initially enriched and se-
quenced with the AVENIO Targeted panel. To validate variants detected with the
Targeted panel and to potentially identify further mutations in an extended genomic target
region, all plasma samples were repeatedly enriched and sequenced with the AVENIO
Surveillance panel. All protocols were conducted according to the manufacturer’s recom-
mendations. Enriched libraries were sequenced on an Illumina NextSeq550 using the
High Output Kit V2 (300 cycles) according to the manufacturer’s protocol (Illumina) with a
median unique target sequence coverage of 7760× (range 4177×–10,869×). Automated
raw data processing and data analysis was performed with the AVENIO ctDNA analysis soft-
ware (Roche). Manual QC of called variants and visualization of aligned reads spanning the
DNA breakpoints in KLC1 intron 9 and ALK intron 19 was done using the Integrative
Genomics Viewer (IGV) (Robinson et al. 2017).
For low-coverage sWGS, sequencing libraries were prepared from 2.5 ng cell-free DNA
using the KAPA Hyper Prep Kit with KAPA Dual-Indexed Adapters for Illumina platforms
(both Roche). Following sequencing adapter ligation for 15 h at 16°C to achieve high ligation
efficiency, libraries were amplified in 11 PCR cycles and purified according to the manufac-
turer’s protocol. Samples were sequenced in a multiplex of 48 sWGS libraries per lane on an
Illumina HiSeq4000 with 100-bp paired-end reads (Illumina). Raw sequencing reads were
processed and aligned using the automated pipeline OTP (Reisinger et al. 2017).
Genome-wide copy number profiles were estimated from low-coverage sWGS data of
ctDNA using ichorCNA (Adalsteinsson et al. 2017), and t-MAD scores were calculated to
quantify CNVs (Mouliere et al. 2018).
For protein analysis, serumwas isolated fromblood samples and centrifuged 30min after
collection to ensure complete coagulation. Serum CEA and CYFRA 21–1 levels were deter-
mined from 10 µL of serum bymultiplexed flow cytometry using theMILLIPLEXMAP Human
Circulating Cancer Biomarker Magnetic Bead Panel (Merck) with the Luminex Bio-Plex 200
immunoassay platform (Bio-Rad). All protocols were conducted according to the manufac-
turer’s recommendations.
Plasma and serum biosamples have been provided by Lungbiobank Heidelberg/BMBH
in accordance with the regulations of the BMBH and the approval of the ethics committee of
the University of Heidelberg. Analysis of clinical data and tissue and blood samples of the
patient in this study was performed after informed consent and approval by the ethics com-
mittee of Heidelberg University (S-270/2001 and S-296/2016).
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VARIANT INTERPRETATION
The median survival of ALK-rearranged non-small-cell lung cancer (ALK+ NSCLC) patients
treated with tyrosine kinase inhibitors (TKIs) currently exceeds 5 yr, but clinical courses
vary widely (Duruisseaux et al. 2017). Recent studies have demonstrated the association of
this clinical heterogeneity with specific molecular tumor characteristics, such as the exact
type of ALK fusion variant, including non-EML4 fusions, as well as the presence of TP53
and other mutations (Christopoulos et al. 2018a,b; Kang et al. 2018; Kron et al. 2018;
Christopoulos et al. 2019a,c). Thus, broader molecular profiling of ALK+ NSCLC, using, for
example, RNA-/DNA-NGS appears to provide information about several clinically relevant
parameters that could be used to optimize therapies and personalized patient treatment be-
yond the readout obtainable from immunohistochemistry and FISH (Volckmar et al. 2019).
In the lung adenocarcinoma case presented here, a translocation of the ALK gene locus
was initially detected by FISH analysis. Subsequent RNA sequencing identified fusion tran-
scripts with exon 9 of KLC1 fused to ALK exon 20 (K9–A20), which has been detected only at
the RNA level in the past, without any information about TKI sensitivity (Togashi et al. 2012).
To the best of our knowledge, our study is the first report of the exact intronic double-strand
breakpoints and the resulting interchromosomal rearrangement for a KLC1–ALK fusion,
which we could identify using hybridization-based deep ctDNA sequencing (Table 1; Fig.
1B). Our results show that the KLC1–ALK fusion of our patient encompasses the DNA se-
quence encoding the 5′-end part of KLC1, including the promoter domain, together with
the sequence coding for the intracellular part of the ALK protein, including the entire tyro-
sine kinase domain, suggesting sensitivity to treatment with ALK inhibitors. Indeed, the pa-
tient showed a good response to crizotinib with partial tumor remission and is—to the best of
our knowledge—the first KLC1–ALK NSCLC case successfully treated with ALK TKI in the
literature.
At the time of failure for any treatment, be it chemotherapy, crizotinib, or after cerebral
radiotherapy (Fig. 1D, I1), disease progression was detectable in liquid biopsies as increasing
VAF of the KLC1–ALK fusion and rising protein tumor markers. Moreover, at the time of ce-
rebral disease progression with multiple new brain lesions under crizotinib (Fig. 1E,I3),
ctDNA assessment identified four distinct mutations in the ALK kinase domain, which poten-
tially cause the progression (Table 1; Fig. 1B). Three out of the four (ALK c.3522C>G, ALK
c.3522C>G/A, and c.3521T>G) encode the p.F1174C/L variants, which are associated
Table 1. Genomic findings
Gene Chr HGVS DNA ref
HGVS
Protein
















ALK 2 c.3521T>G p.F1174C Substitution Crizotinib
resistance
0.27% 10,316× 28
ALK 2 c.3522C>A p.F1174L Substitution Crizotinib
resistance
0.79% 10,192× 81
ALK 2 c.3522C>G p.P1174L Substitution Crizotinib
resistance
3.26% 10,192× 332
ALK 2 c.3806G>C p.G1269A Substitution Crizotinib
resistance
0.51% 16,190× 83
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with resistance to ceritinib and crizotinib (Gainor et al. 2016; Lin et al. 2017). The fourth mu-
tation (ALK c.3806G>C) encodes the p.G1269A variant, which is associated with resistance
to crizotinib (Gainor et al. 2016). Interestingly, the four secondary mutations show similar
courses over time, suggesting a parallel evolution of multiple resistant clones with distinct
molecular resistance mechanisms. Although Gainor et al. detected all these resistance mu-
tations in tissue specimens obtained from progressing EML4–ALK-rearranged tumors, our
report is the first to describe these mutations occurring simultaneously in ctDNA of a
KLC1–ALK patient progressing under crizotinib. In line with this finding, recent proof-of-con-
cept studies also demonstrated the feasibility of identifying and tracking resistance muta-
tions to ALK inhibitors with serial liquid biopsies (Dagogo-Jack et al. 2018; De Carlo et al.
2018; McCoach et al. 2018), illustrating the potential utility of plasma ctDNA genotyping
in the clinical patient management in ALK+ NSCLC (Rolfo et al. 2018). Besides ALK+
NSCLC, several studies demonstrated the potential of ctDNA typing for cancer detection,
molecular profiling, therapy monitoring, and identification of treatment resistance in various
tumor entities (Murtaza et al. 2013; Abbosh et al. 2017; Wan et al. 2017; Cohen et al. 2018).
Finally, although imaging suggested stable disease after radiotherapy with remission of the
cerebral lesions, rising ctDNA levels of the KLC1–ALK fusion and of all four secondary ALK
point mutations suggested poor disease control. Importantly, this was accompanied by ris-
ing concentrations of both protein tumor markers CEA and CYFRA 21–1 in synchronous se-
rum samples (Fig. 1C), and confirmed by the subsequent clinical course, which showed
multifocal radiologic progression a few weeks later in conjunction with further increases in
all ctDNA and protein markers.
Panel sequencing utilizes enrichment of specific loci and enables deep sequencing to
detect recurrent hotspot or resistance mutations; however, it is limited to mutations within
the target regions. In contrast, whole-genome or -exome sequencing of plasma DNA facil-
itates comprehensivemolecular profiling, including de novomutations and CNVs, but is only
feasible for increased ctDNA fractions as the analytical sensitivity is limited by the relatively
low coverage. Increasing the tumor-derived fraction of cell-free DNA could help to over-
come this limitation and to improve the detection of somatic aberrations at lower sequencing
depths (Mouliere et al. 2018). Here, we demonstrate a complementary use of targeted deep
sequencing and low-coverage sWGS. In addition tomutation typing, we performed sWGS of
cell-free DNA to assess CNV profiles at the genome-scale. Prior to crizotinib initiation, no
CNVs were detected in the plasma sample of our patient. In contrast, remarkable alterations
with fourfold t-MAD increase were detected at the end of treatment, including an amplifica-
tion of a region on Chromosome 12 encompassing the TP53 regulator geneMDM2 (Fig. 1C,
E). MDM2 amplifications have been directly associated with worse prognosis and TKI resis-
tance in RET-rearranged lung cancers (Dworakowska et al. 2004; Somwar et al. 2016), where-
as impairment of TP53 function, as would be expected with MDM2 overexpression, is an
important determinant of poor survival in ALK+ NSCLC, either at baseline or if acquired dur-
ing the course of the disease (Kron et al. 2018; Christopoulos et al. 2019b,c). Thus, although
the presence of the amplification in the baseline cannot be excluded because of the overall
low ctDNA fraction in this sample, the findings suggest that CNVs, including theMDM2 am-
plification, might contribute to the progression of ALK+ NSCLC patients beyond secondary
mutations in the ALK kinase domain.
SUMMARY
We report the first case of KLC1–ALK-rearranged lung adenocarcinoma responding to treat-
ment with crizotinib and demonstrate the utility of multiple plasma and serum biomarkers for
identification of ALK fusion partners and longitudinal disease monitoring in ALK+ NSCLC. At
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the time of treatment, failure under chemotherapy, crizotinib and cerebral radiotherapy, ris-
ing allelic frequencies of the ALK fusion, distinct ALK resistance mutations (in case of TKI),
emerging CNV, and increasing concentrations of protein markers reflected the poor disease
control and predicted the subsequent clinical deterioration, in part earlier and more reliably
than radiologic findings. Our findings illustrate the potential clinical utility of noninvasive lon-
gitudinal molecular profiling for assessing remission status, exploring mechanisms of treat-
ment failure, predicting subsequent clinical course, and dissecting dynamics of drug-
resistant clones in ALK+ lung cancer.
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Gulida G, Szymanowska A, Skokowski J, et al. 2004.MDM2 gene amplification: a new independent factor
of adverse prognosis in non–small cell lung cancer (NSCLC). Lung Cancer 43: 285–295. doi:10.1016/j
.lungcan.2003.09.010
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K,
Singh M, et al. 2016. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors
in ALK-rearranged lung cancer. Cancer Discov 6: 1118–1133. doi:10.1158/2159-8290.CD-16-0596
Kang J, Zhang XC, Chen HJ, Zhou Q, Tu HY, Li WF. 2018. Uncommon ALK fusion partners in advanced ALK-
positive non-small-cell lung cancer. J Clin Oncol 36: 8561. doi:10.1200/JCO.2018.36.15_suppl.8561
Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L,
Fassunke J, et al. 2018. Impact of TP53mutation status on systemic treatment outcome in ALK-rearranged
non-small-cell lung cancer. Ann Oncol 29: 2068–2075. doi:10.1093/annonc/mdy333
Lin JJ, Riely GJ, Shaw AT. 2017. Targeting ALK: precision medicine takes on drug resistance.Cancer Discov 7:
137–155. doi:10.1158/2159-8290.CD-16-1123
McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, et al.
2018. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK in-
hibitor resistance in non-small cell lung cancer. Clin Cancer Res 24: 2758–2770. doi:10.1158/1078-0432
.CCR-17-2588
Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F,
Heider K, et al. 2018. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl
Med 10: eaat4921. doi:10.1126/scitranslmed.aat4921
Murtaza M, Dawson SJ, Tsui DWY, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong
ASC, et al. 2013. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma
DNA. Nature 497: 108–112. doi:10.1038/nature12065
Pfarr N, Stenzinger A, Penzel R, Warth A, Dienemann H, Schirmacher P, Weichert W, Endris V. 2016. High-
throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes Chromosomes
Cancer 55: 30–44. doi:10.1002/gcc.22297
Circulating resistance markers in KLC1–ALK NSCLC
C O L D S P R I N G H A R B O R
Molecular Case Studies
Dietz et al. 2019 Cold Spring Harb Mol Case Stud 5: a004630 8 of 9
 Cold Spring Harbor Laboratory Press on April 7, 2021 - Published by molecularcasestudies.cshlp.orgDownloaded from 
Reisinger E, Genthner L, Kerssemakers J, Kensche P, Borufka S, Jugold A, KlingA, PrinzM, Scholz I, ZipprichG,
et al. 2017. OTP: an automatized system for managing and processingNGS data. J Biotechnol 261: 53–62.
doi:10.1016/j.jbiotec.2017.08.006
Robinson JT, Thorvaldsdóttir H, Wenger AM, Zehir A, Mesirov JP. 2017. Variant reviewwith the integrative ge-
nomics viewer. Cancer Res 77: E31–E34. doi:10.1158/0008-5472.CAN-17-0337
Rolfo C,Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, et al. 2018.
Liquid biopsy for advanced non–small cell lung cancer (NSCLC): a statement paper from the IASLC. J
Thorac Oncol 13: 1248–1268. doi:10.1016/j.jtho.2018.05.030
Somwar R, Smith R, Hayashi T, Ishizawa K, Charen AS, Khodos I, Mattar M, He J, Balasubramanian S, Stephens
P, et al. 2016. MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with ad-
vanced RET-rearranged lung cancers. J Clin Oncol 34: 9068. doi:10.1200/JCO.2016.34.15_suppl.9068
Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, Nakajima T, Mano H, Takeuchi K. 2012. KLC1-
ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS
One 7: e31323. doi:10.1371/journal.pone.0031323
Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, de Oliveira CMM, Rempel
E, Buchhalter I, Brandt R, et al. 2019. Combined targeted DNA and RNA sequencing of advanced NSCLC
in routine molecular diagnostics: analysis of the first 3,000 Heidelberg cases. Int J Cancer 145: 649–661.
doi:10.1002/ijc.32133
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N.
2017. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer
17: 223–238. doi:10.1038/nrc.2017.7
Circulating resistance markers in KLC1–ALK NSCLC
C O L D S P R I N G H A R B O R
Molecular Case Studies
Dietz et al. 2019 Cold Spring Harb Mol Case Stud 5: a004630 9 of 9
 Cold Spring Harbor Laboratory Press on April 7, 2021 - Published by molecularcasestudies.cshlp.orgDownloaded from 
 10.1101/mcs.a004630Access the most recent version at doi:
 a004630 originally published online November 21, 20195:2019, Cold Spring Harb Mol Case Stud 
  
Steffen Dietz, Petros Christopoulos, Lisa Gu, et al. 
  
-rearranged lung cancerALK−KLC1of resistance mechanisms in 





This article cites 27 articles, 5 of which can be accessed free at:
  
License
for commercial purposes, provided that the original author and source are credited.
Attribution-NonCommercial License, which permits reuse and redistribution, except 




 click here.top right corner of the article or 
Receive free email alerts when new articles cite this article - sign up in the box at the
© 2019 Dietz et al.; Published by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on April 7, 2021 - Published by molecularcasestudies.cshlp.orgDownloaded from 
